Dopamine system deficiencies and associated behavioral phenotypes may be a critical barrier to success in treating stimulant use disorders. Similarities in dopamine dysfunction between cocaine and methamphetamine use disorder but also key differences may impact treatment efficacy and outcome. This review will first compare the epidemiology of cocaine and methamphetamine use disorder. A detailed account of the pharmacokinetic and pharmacodynamic properties associated with each drug will then be discussed, with an emphasis on effects on the dopamine system and associated signaling pathways. Lastly, treatment results from pharmacological clinical trials will be summarized along with a more comprehensive review of the involvement of the trace amine-associated receptor on dopamine signaling dysfunction among stimulants and its potential as a therapeutic target.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
World Drug Report 2020. United Nations Publication, Sales No. E.20.XI.6; 2020.
Koob GF. Circuits, drugs, and drug addiction. Adv Pharm. 1998;42:978–82.
Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74:511–9.
Proebstl L, Kamp F, Manz K, Krause D, Adorjan K, Pogarell O, et al. Effects of stimulant drug use on the dopaminergic system: a systematic review and meta-analysis of in vivo neuroimaging studies. Eur Psychiatry. 2019;59:15–24.
Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharm. 2001;60:1181–8.
Oregon-Idaho High Intensity Drug Trafficking Area. Annual Report; 2019.
Drug Enforcement Administration. 2019 National drug threat assessment Annual Drug Report. Springfield, Virginia: US Department of Justice, Drug Enforcement Administration; 2019.
Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry. 2007;64:495–502.
Cheng YC, Ryan KA, Qadwai SA, Shah J, Sparks MJ, Wozniak MA, et al. Cocaine use and risk of ischemic stroke in young adults. Stroke. 2016;47:918–22.
Callaghan RC, Halliday M, Gatley J, Sykes J, Taylor L, Benny C, et al. Comparative hazards of acute myocardial infarction among hospitalized patients with methamphetamine- or cocaine-use disorders: a retrospective cohort study. Drug Alcohol Depend. 2018;188:259–65.
Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13:181–90.
Boles S, Miotto K. Substance abuse and violence: a review of the literature. Aggression Violent Behav. 2003;8:155–74.
Vik PW. Methamphetamine use by incarcerated women: comorbid mood and anxiety problems. Women’s Health Issues. 2007;17:256–63.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Identifying methamphetamine users at risk for major depressive disorder: findings from the methamphetamine treatment project at three-year follow-up. Am J Addict. 2008;17:99–102.
London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73–84.
Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addictions. 2004;13:248–55.
Semple SJ, Zians J, Strathdee SA, Patterson TL. Psychosocial and behavioral correlates of depressed mood among female methamphetamine users. J Psychoactive Drugs. 2007;Suppl 4:353–66. https://doi.org/10.1080/02791072.2007.10399897.
Alexander PD, Gicas KM, Willi TS, Kim CN, Boyeva V, Procyshyn RM, et al. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology (Berlin). 2017;234:1535–47.
Gizzi MC, Gerkin P. Methamphetamine use and criminal behavior. Int J Offender Ther Comp Criminol. 2010;54:915–36.
Hoffman WF, Jacobs MB, Dennis LE, McCready HD, Hickok AW, Smith SB, et al. Psychopathy and corticostriatal connectivity: the link to criminal behavior in methamphetamine dependence. Front Psychiatry. 2020;11:90.
Taylor S, Lewis C, Olive M. The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans. Subst Abus Rehabil. 2013;4:29–73.
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharm. 2010;69:578–92.
Goodwin JS, Larson GA, Swant J, Sen N, Javitch JA, Zahniser NR, et al. Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem. 2009;284:2978–89.
Kohno M, Link J, Dennis LE, McCready H, Huckans M, Hoffman WF, et al. Neuroinflammation in addiction: a review of neuroimaging studies and potential immunotherapies. Pharm Biochem Behav. 2019;179:34–42.
Yamamoto BK, Moszczynska A, Gudelsky GA. Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci. 2010;1187:101–21.
Jufer RA, Wstadik A, Walsh SL, Levine BS, Cone EJ. Elimination of cocaine and metabolites in plasma, saliva, and urine following repeated oral administration to human volunteers. J Anal Toxicol. 2000;24:467–77.
Harris DS, Boxenbaum H, Everhart ET, Sequeira G, Mendelson JE, Jones RT. The bioavailability of intranasal and smoked methamphetamine. Clin Pharm Ther. 2003;74:475–86.
Feltenstein MW, See RE. Systems level neuroplasticity in drug addiction. Cold Spring Harb Perspect Med. 2013;3:a011916.
Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, et al. Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. NeuroImage. 2008;43:756–63.
Vergo S, Johansen JL, Leist M, Lotharius J. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 2007;1185:18–32.
Volz TJ, Hanson GR, Fleckenstein AE. The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficits. J Neurochem. 2007;101:883–8.
Pereira FC, Lourenco ES, Borges F, Morgadinho T, Ribeiro CF, Macedo TR, et al. Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen. Synapse. 2006;60:185–93.
Ritz MC, Kuhar MJ. Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharm Exp Ther. 1989;248:1010–7.
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–23.
Roberts DC, Corcoran ME, Fibiger HC. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharm Biochem Behav. 1977;6:615–20.
Lyness WH, Friedle NM, Moore KE. Destruction of dopaminergic nerve terminals in nucleus accumbens: effect on d-amphetamine self-administration. Pharm Biochem Behav. 1979;11:553–6.
Roberts DC, Koob GF, Klonoff P, Fibiger HC. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharm Biochem Behav. 1980;12:781–7.
Pettit HO, Ettenberg A, Bloom FE, Koob GF. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berlin). 1984;84:167–73.
Caine SB, Koob GF. Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharm Exp Ther. 1994;270:209–18.
Caine SB, Koob GF. Effects of mesolimbic dopamine depletion on responding maintained by cocaine and food. J Exp Anal Behav. 1994;61:213–21.
Koob GF, Caine B, Markou A, Pulvirenti L, Weiss F. Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Res Monogr. 1994;145:1–18.
Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharm Exp Ther. 1999;291:409–15.
Weiss F, Markou A, Lorang MT, Koob GF. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 1992;593:314–8.
O’Dell SJ, Weihmuller FB, Marshall JF. Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res. 1991;564:256–60.
Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85:5274–8.
Wallace TL, Gudelsky GA, Vorhees CV. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci. 1999;19:9141–8.
Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, et al. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996;40:428–39.
Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry. 2003;160:47–55.
Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med. 1996;2:699–703.
Melega WP, Jorgensen MJ, Lacan G, Way BM, Pham J, Morton G, et al. Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. Neuropsychopharmacology. 2008;33:1441–52.
Groman SM, Lee B, Seu E, James AS, Feiler K, Mandelkern MA, et al. Dysregulation of D(2)-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure. J Neurosci. 2012;32:5843–52.
Zhu JP, Xu W, Angulo JA. Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res. 2005;1049:171–81.
German CL, Hanson GR, Fleckenstein AE. Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem. 2012;123:288–97.
Thanos PK, Kim R, Delis F, Rocco MJ, Cho J, Volkow ND. Effects of chronic methamphetamine on psychomotor and cognitive functions and dopamine signaling in the brain. Behav Brain Res. 2017;320:282–90.
Izenwasser S. The role of the dopamine transporter in cocaine abuse. Neurotox Res. 2004;6:379–83.
Letchworth SR, Nader MA, Smith HR, Friedman DP, Porrino LJ. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J Neurosci. 2001;21:2799–807.
Kitamura O. Detection of methamphetamine neurotoxicity in forensic autopsy cases. Leg Med (Tokyo). 2009;11:S63–65.
Little KY, McLaughlin DP, Zhang L, McFinton PR, Dalack GW, Cook EH, et al. Brain dopamine transporter messenger RNA and binding sites in cocaine users: a postmortem study. Arch Gen Psychiatry. 1998;55:793–9.
Narendran R, Martinez D. Cocaine abuse and sensitization of striatal dopamine transmission: a critical review of the preclinical and clinical imaging literature. Synapse. 2008;62:851–69.
Richtand NM, Woods SC, Berger SP, Strakowski SM. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev. 2001;25:427–43.
Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 1997;19:837–48.
Pritchard LM, Newman AH, McNamara RK, Logue AD, Taylor B, Welge JA, et al. The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharm Biochem Behav. 2007;86:718–26.
Khroyan TV, Baker DA, Fuchs RA, Manders N, Neisewander JL. Differential effects of 7-OH-DPAT on amphetamine-induced stereotypy and conditioned place preference. Psychopharmacology (Berlin). 1998;139:332–41.
Groman SM, Hillmer AT, Liu H, Fowles K, Holden D, Morris ED, et al. Midbrain D3 receptor availability predicts escalation in cocaine self-administration. Biol Psychiatry. 2020;88:767–76.
Neisewander JL, Cheung TH, Pentkowski NS. Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development. Neuropharmacology. 2013;76:301–19.
Richtand NM. Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology. 2006;31:2368–75.
Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, et al. Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. J Neurosci. 2012;32:1353–9.
Boileau I, Payer D, Rusjan PM, Houle S, Tong J, McCluskey T, et al. Heightened dopaminergic response to amphetamine at the D3 dopamine receptor in methamphetamine users. Neuropsychopharmacology. 2016;41:2994–3002.
Matuskey D, Gallezot JD, Pittman B, Williams W, Wanyiri J, Gaiser E, et al. Dopamine D(3) receptor alterations in cocaine-dependent humans imaged with [(1)(1)C](+)PHNO. Drug Alcohol Depend. 2014;139:100–5.
Staley JK, Mash DC. Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci. 1996;16:6100–6.
Matuskey D, Gaiser EC, Gallezot JD, Angarita GA, Pittman B, Nabulsi N, et al. A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO. Drug Alcohol Depend. 2015;154:167–73.
Worhunsky PD, Matuskey D, Gallezot JD, Gaiser EC, Nabulsi N, Angarita GA, et al. Regional and source-based patterns of [(11)C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder. Neuroimage. 2017;148:343–51.
Mello NK, Negus SS. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology. 1996;14:375–424.
Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berlin). 2002;163:265–82.
Self DW, Stein L. The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Res. 1992;582:349–52.
Weed MR, Woolverton WL. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. J Pharm Exp Ther. 1995;275:1367–74.
Grech DM, Spealman RD, Bergman J. Self-administration of D1 receptor agonists by squirrel monkeys. Psychopharmacology (Berl). 1996;125:97–104.
Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL. The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys. J Pharm Exp Ther. 1997;283:29–38.
Self DW, Belluzzi JD, Kossuth S, Stein L. Self-administration of the D1 agonist SKF 82958 is mediated by D1, not D2, receptors. Psychopharmacology (Berlin). 1996;123:303–6.
Graziella De Montis M, Co C, Dworkin SI, Smith JE. Modifications of dopamine D1 receptor complex in rats self-administering cocaine. Eur J Pharm. 1998;362:9–15.
Moore RJ, Vinsant SL, Nader MA, Porrino LJ, Friedman DP. Effect of cocaine self-administration on striatal dopamine D1 receptors in rhesus monkeys. Synapse. 1998;28:1–9.
Tomic M, Vukosavic S, Joksimovic J. Acute amphetamine and/or phencyclidine effects on the dopamine receptor specific binding in the rat brain. Eur Neuropsychopharmacol. 1997;7:295–301.
Ujike H, Akiyama K, Nishikawa H, Onoue T, Otsuki S. Lasting increase in D1 dopamine receptors in the lateral part of the substantia nigra pars reticulata after subchronic methamphetamine administration. Brain Res. 1991;540:159–63.
Nonaka R, Moroji T. Effects of chronic methamphetamine treatment on the binding parameters of [3H]SCH 23390, a selective D1-dopamine receptor ligand, in the rat brain. Neurosci Lett. 1990;120:109–12.
Martinez D, Slifstein M, Narendran R, Foltin RW, Broft A, Hwang DR, et al. Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine. Neuropsychopharmacology. 2009;34:1774–82.
Okita K, Morales AM, Dean AC, Johnson MC, Lu V, Farahi J, et al. Striatal dopamine D1-type receptor availability: no difference from control but association with cortical thickness in methamphetamine users. Mol Psychiatry. 2018;23:1320–7.
Worsley JN, Moszczynska A, Falardeau P, Kalasinsky KS, Schmunk G, Guttman M, et al. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users. Mol Psychiatry. 2000;5:664–72.
Smout MF, Longo M, Harrison S, Minniti R, Wickes W, White JM. Psychosocial treatment for methamphetamine use disorders: a preliminary randomized controlled trial of cognitive behavior therapy and acceptance and commitment therapy. Subst Abus. 2010;31:98–107.
Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction. 2004;99:708–17.
AshaRani PV, Hombali A, Seow E, Ong WJ, Tan JH, Subramaniam M. Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020;212:108060.
Rawson RA, McCann MJ, Flammino F, Shoptaw S, Miotto K, Reiber C, et al. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. Addiction. 2006;101:267–74.
Carroll KM, Onken LS. Behavioral therapies for drug abuse. Am J Psychiatry. 2005;162:1452–60.
Bhatt M, Zielinski L, Baker-Beal L, Bhatnagar N, Mouravska N, Laplante P, et al. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis. Syst Rev. 2016;5:189.
Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology (Berlin). 2020;237:2233–55.
Castells X, Cunill R, Perez-Mana C, Vidal X, Capella D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:CD007380.
Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. J Gen Intern Med. 2019;34:2858–73.
Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, et al. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis. Addiction. 2019;114:2122–36.
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME. In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharm Exp Ther. 2016;357:134–44.
Harkness JH, Shi X, Janowsky A, Phillips TJ. Trace amine-associated receptor 1 regulation of methamphetamine intake and related traits. Neuropsychopharmacology. 2015;40:2175–84.
Phillips TJ, Shabani S. An animal model of differential genetic risk for methamphetamine intake. Front Neurosci. 2015;9:327.
Lindemann L, Meyer CA, Jeanneau K, Bradaia A, Ozmen L, Bluethmann H, et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharm Exp Ther. 2008;324:948–56.
Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. Am J Psychiatry. 2011;168:634–41.
Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2012;17:918–25.
Shi X, Walter NA, Harkness JH, Neve KA, Williams RW, Lu L, et al. Genetic polymorphisms affect mouse and human trace amine-associated receptor 1 function. PLoS ONE. 2016;11:e0152581.
Loftis JM, Lasarev M, Shi X, Lapidus J, Janowsky A, Hoffman WF, et al. Trace amine-associated receptor gene polymorphism increases drug craving in individuals with methamphetamine dependence. PLoS ONE. 2019;14:e0220270.
Muhlhaus J, Dinter J, Jyrch S, Teumer A, Jacobi SF, Homuth G, et al. Investigation of naturally occurring single-nucleotide variants in human TAAR1. Front Pharm. 2017;8:807.
John J, Kukshal P, Bhatia T, Chowdari KV, Nimgaonkar VL, Deshpande SN, et al. Possible role of rare variants in trace amine associated receptor 1 in schizophrenia. Schizophr Res. 2017;189:190–5.
Rutigliano G, Bräunig J, Del Grande C, Carnicelli V, Masci I, Merlino S, et al. Non-functional trace amine-associated receptor 1 variants in patients with mental disorders. Front Pharmacol. 2019;10:1027. https://doi.org/10.3389/fphar.2019.01027.
Berry MD, Gainetdinov RR, Hoener MC, Shahid M. Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharm Ther. 2017;180:161–80.
Pei Y, Asif-Malik A, Canales JJ. Trace amines and the trace amine-associated receptor 1: pharmacology, neurochemistry, and clinical implications. Front Neurosci. 2016;10:148.
Underhill SM, Hullihen PD, Chen J, Fenollar-Ferrer C, Rizzo MA, Ingram SL, et al. Amphetamines signal through intracellular TAAR1 receptors coupled to Galpha13 and GalphaS in discrete subcellular domains. Mol Psychiatry. 2021;26:1208–23.
Underhill SM, Wheeler DS, Li M, Watts SD, Ingram SL, Amara SG. Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron. 2014;83:404–16.
Underhill SM, Ingram SL, Ahmari SE, Veenstra-VanderWeele J, Amara SG. Neuronal excitatory amino acid transporter EAAT3: emerging functions in health and disease. Neurochem Int. 2019;123:69–76.
Scheyer AF, Loweth JA, Christian DT, Uejima J, Rabei R, Le T, et al. AMPA receptor plasticity in accumbens core contributes to incubation of methamphetamine craving. Biol Psychiatry. 2016;80:661–70.
Murray CH, Loweth JA, Milovanovic M, Stefanik MT, Caccamise AJ, Dolubizno H, et al. AMPA receptor and metabotropic glutamate receptor 1 adaptations in the nucleus accumbens core during incubation of methamphetamine craving. Neuropsychopharmacology. 2019;44:1534–41.
Revel FG, Moreau JL, Gainetdinov RR, Bradaia A, Sotnikova TD, Mory R, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci USA. 2011;108:8485–90.
Revel FG, Meyer CA, Bradaia A, Jeanneau K, Calcagno E, Andre CB, et al. Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology. 2012;37:2580–92.
Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, et al. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25:2049–61.
Liu J, Wu R, Li JX. TAAR1 and psychostimulant addiction. Cell Mol Neurobiol. 2020;40:229–38.
Pei Y, Asif-Malik A, Hoener M, Canales JJ. A partial trace amine-associated receptor 1 agonist exhibits properties consistent with a methamphetamine substitution treatment. Addict Biol. 2017;22:1246–56.
Robertson CL, Ishibashi K, Chudzynski J, Mooney LJ, Rawson RA, Dolezal BA, et al. Effect of exercise training on striatal dopamine D2/D3 receptors in methamphetamine users during behavioral treatment. Neuropsychopharmacology. 2016;41:1629–36.
Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend. 2009;105:48–55.
This work was supported in part by the Department of Veterans Affairs Clinical Sciences Research and Development Merit Review Program, I01 CX001558-01A1 (WFH); Department of Justice 2010-DD-BX-0517 (WFH); National Institute on Drug Abuse P50DA018165 (WFH), and R21 DA047602-01A1 (WFH); Oregon Clinical and Translational Research Institute, 1 UL1 RR024140 01 from the National Center for Research Resources, a component of the National Institutes of Health and National Institute of Health Roadmap for Medical Research (WFH) and National Institute on Alcohol Abuse and Alcoholism R21 AA020039 (WFH). MK was supported by Department of Veterans Affairs Clinical Sciences Research and Development Career Development Award CX001790, Oregon Health & Science University Collins Medical Trust Award APSYC0249, Medical Research Foundation of Oregon APSYC0250 and Center for Women’s Health Circle of Giving GPSYC0287A.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kohno, M., Dennis, L.E., McCready, H. et al. Dopamine dysfunction in stimulant use disorders: mechanistic comparisons and implications for treatment. Mol Psychiatry 27, 220–229 (2022). https://doi.org/10.1038/s41380-021-01180-4